EGFR and lung carcinoma: ,5,42 This is exemplified by the distinct and broader spectrum of resistance mutations (e.g., at G12, G13, Q61, R68, Y96, H95) observed in KRASG12C-mutant NSCLC compared to the more uniform T790M-mediated resistance, which accounts for 50–60% of acquired resistance to EGFR-TKIs in EGFR-mutant lung cancer.30